Are You Struggling
with Mitral Regurgitation?

You may be eligible for a new clinical trial that includes a minimally-invasive option for mitral valve replacement.

Learn More

Patients With Mitral Regurgitation May Be Eligible
For A Minimally-Invasive Mitral Valve Replacement

The purpose of the SUMMIT Clinical Trial is to evaluate the Tendyne™ Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.

Watch this educational video to learn about the SUMMIT Clinical Trial that will evaluate the Tendyne™ Mitral Valve System.

What Is Transcatheter Mitral Valve Replacement (TMVR)?

Transcatheter Mitral Valve Replacement (TMVR) is a minimally-invasive treatment option for patients with mitral regurgitation. During TMVR, a Tendyne™ device is inserted through a catheter into the heart. The Tendyne™ valve replaces the defective mitral valve to prevent mitral regurgitation. TMVR is performed without an incision to the patient’s sternum and the patient does not need to be on a heart-lung machine.

Watch this video to see how a Tendyne™ device is positioned in the heart.

Imporant facts about TMVR include:

  • TMVR is a less-invasive procedure than surgical mitral valve replacement.
  • TMVR uses catheters to access and replace the mitral valve.
  • TMVR does not require the patient to be on a heart-lung machine.
  • TMVR is only performed by doctors who have extensive and specialized training.

Who Can Participate In
The SUMMIT Clinical Trial?

Doctors and research teams that specialize in mitral valve therapy can determine if you are eligible to participate in the SUMMIT Clinical Trial for mitral regurgitation patients. You may qualify if:

You have been diagnosed with mitral regurgitation

You are 18 years of age or older

A heart team determines that a transcather mitral valve replacement may be appropriate for you.

Find Out If You Qualify For The SUMMIT Clinical Trial

Approximately 800 patients will participate in the SUMMIT Clinical Trial at 80 medical centers across the United States, Canada and Europe. A team of medical experts who specialize in mitral valve therapy will monitor all patients who enroll in the SUMMIT Clinical Trial.

For more information about the SUMMIT Clinical Trial and a full list of clinical sites, please visit

Learn More At

Download Free Brochure To Learn More

To learn more about mitral regurgitation (symptoms, causes and risks), treatment options, and the SUMMIT Clinical Trial, please download our free brochure.

Download Free Patient Brochure

The educational information provided on this page is sponsored by Abbott. Learn more.